These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 34753229)
21. Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor. Deniger DC; Switzer K; Mi T; Maiti S; Hurton L; Singh H; Huls H; Olivares S; Lee DA; Champlin RE; Cooper LJ Mol Ther; 2013 Mar; 21(3):638-47. PubMed ID: 23295945 [TBL] [Abstract][Full Text] [Related]
22. CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models. Tsukahara T; Ohmine K; Yamamoto C; Uchibori R; Ido H; Teruya T; Urabe M; Mizukami H; Kume A; Nakamura M; Mineno J; Takesako K; Riviere I; Sadelain M; Brentjens R; Ozawa K Biochem Biophys Res Commun; 2013 Aug; 438(1):84-9. PubMed ID: 23872144 [TBL] [Abstract][Full Text] [Related]
23. Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19. Ormhøj M; Scarfò I; Cabral ML; Bailey SR; Lorrey SJ; Bouffard AA; Castano AP; Larson RC; Riley LS; Schmidts A; Choi BD; Andersen RS; Cédile O; Nyvold CG; Christensen JH; Gjerstorff MF; Ditzel HJ; Weinstock DM; Barington T; Frigault MJ; Maus MV Clin Cancer Res; 2019 Dec; 25(23):7046-7057. PubMed ID: 31439577 [TBL] [Abstract][Full Text] [Related]
24. CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome. Pecher AC; Hensen L; Klein R; Schairer R; Lutz K; Atar D; Seitz C; Stanger A; Schneider J; Braun C; Schmidt M; Horger M; Bornemann A; Faul C; Bethge W; Henes J; Lengerke C JAMA; 2023 Jun; 329(24):2154-2162. PubMed ID: 37367976 [TBL] [Abstract][Full Text] [Related]
25. Activity of Anti-CD19 Chimeric Antigen Receptor T Cells Against B Cell Lymphoma Is Enhanced by Antibody-Targeted Interferon-Alpha. Young PA; Yamada RE; Trinh KR; Vasuthasawat A; De Oliveira S; Yamada DH; Morrison SL; Timmerman JM J Interferon Cytokine Res; 2018 Jun; 38(6):239-254. PubMed ID: 29920129 [TBL] [Abstract][Full Text] [Related]
26. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients. Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128 [TBL] [Abstract][Full Text] [Related]
27. [Construction of specific artificial antigen-presenting cells for in vitro activation of CD19 chimeric antigen receptor T cells]. Peng YJ; Wu QY; Liu HY; Zhao J; Wei HF Nan Fang Yi Ke Da Xue Xue Bao; 2017 May; 37(5):581-587. PubMed ID: 28539278 [TBL] [Abstract][Full Text] [Related]
28. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells. An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021 [TBL] [Abstract][Full Text] [Related]
29. Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy. Yang M; Wang L; Ni M; Neuber B; Wang S; Gong W; Sauer T; Schubert ML; Hückelhoven-Krauss A; Xia R; Ge J; Kleist C; Eckstein V; Sellner L; Müller-Tidow C; Dreger P; Schmitt M; Schmitt A Front Immunol; 2021; 12():670088. PubMed ID: 34122428 [TBL] [Abstract][Full Text] [Related]
30. [Analysis of local reactions and efficacy of CD19 chimeric antigen receptor-modified T cells therapy in recurrent/refractory B-cell lymphoma with >7.5 cm lesions]. Li Q; Deng HB; Liu MJ; Lyu CC; Zhu HB; Wang J; Jiang YL; Pu YD; Jiang YY; Li W; Deng Q Zhonghua Xue Ye Xue Za Zhi; 2021 Jul; 42(7):570-576. PubMed ID: 34455744 [No Abstract] [Full Text] [Related]
31. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia. Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E Front Immunol; 2019; 10():3123. PubMed ID: 32117200 [TBL] [Abstract][Full Text] [Related]
32. [Establishment of a cytokine release syndrome associated with chimeric antigen receptor T cell treatment in SCID/Beige mice model]. Shan JQ; Nan SF; Li F; Shen CY; Zhang Y Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1248-1254. PubMed ID: 34915632 [No Abstract] [Full Text] [Related]
33. [Construction and in vitro verification of a new humanized anti-CD19 CAR-T cells with high affinity]. Zhang CX; Cheng H; Han X; Qi KM; Chen W; Wu QY; Cao J; Xu KL Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):465-470. PubMed ID: 30032561 [No Abstract] [Full Text] [Related]
35. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy. Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616 [TBL] [Abstract][Full Text] [Related]
36. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model? Palen K; Zurko J; Johnson BD; Hari P; Shah NN Cytotherapy; 2021 Nov; 23(11):985-990. PubMed ID: 34538575 [TBL] [Abstract][Full Text] [Related]
37. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA MAbs; 2015; 7(3):584-604. PubMed ID: 25875246 [TBL] [Abstract][Full Text] [Related]
38. Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study. Thakur A; Scholler J; Schalk DL; June CH; Lum LG J Cancer Res Clin Oncol; 2020 Aug; 146(8):2007-2016. PubMed ID: 32449004 [TBL] [Abstract][Full Text] [Related]
39. [The specific cytotoxicities of chimeric antigen receptor-engineered T cells on different lymphomas]. Zhang R; Deng Q; Sui SN; Jin X; Zhao MF Zhonghua Xue Ye Xue Za Zhi; 2017 Oct; 38(10):842-847. PubMed ID: 29166735 [No Abstract] [Full Text] [Related]
40. Using Oncolytic Virus to Retask CD19-Chimeric Antigen Receptor T Cells for Treatment of Pancreatic Cancer: Toward a Universal Chimeric Antigen Receptor T-Cell Strategy for Solid Tumor. Chen C; Park AK; Monroy I; Ren Y; Kim SI; Chaurasiya S; Priceman SJ; Fong Y J Am Coll Surg; 2024 Apr; 238(4):436-447. PubMed ID: 38214445 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]